Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma With Persistent Lymphovascular Invasion or Lymph Node Involvement After Neoadjuvant Chemotherapy.
Sep 2026· Journal of Surgical Oncology· 0 citations· 24 references
Medicine
TL;DR
LVI and LN involvement were independently associated with worse OS and the use of AT in patients with persistent LVI and LN involvement was not associated with improved OS after NAT.
Abstract
Background
AND
Objectives
There is increasing use of neoadjuvant treatment (NAT) for patients with pancreatic adenocarcinoma (PDAC). The role of additional adjuvant chemotherapy (AT) is not well-defined. This study aims to determine the impact of lymphovascular invasion (LVI) and lymph node (LN) involvement on overall survival (OS) in patients with resected PDAC and determine the impact of AT after NAT.
Methods
This is an observational cohort study of patients with PDAC who underwent NAT and surgical resection. A multivariable model was used to assess for differences in OS. An interaction term between LVI or LN involvement and AT use was utilized to test the benefit of additional AT.
Results
Seven thousand four hundred and fourteen patients were included; group A (LVI-, LN-) had 2787 patients, B (LVI + , LN-) 652, C (LVI-, LN + ) 1,712, and D (LVI + , LN + ) 2263. Median OS differed significantly between groups, A had the most favorable survival (34.1 months), followed by B (27.8 months), C (26.3 months), and D (21.2 months, p < 0.001). In patients with persistent LVI or LN involvement after NAT, additional AT was not associated with OS (group A, HR: 0.94, p = 0.4; B and C, HR: 1.0, p = 0.99; D, HR: 0.94, p = 0.32).
Conclusions
LVI and LN involvement were independently associated with worse OS. After NAT, the use of AT in patients with persistent LVI and LN involvement was not associated with improved OS.
BACKGROUND
For patients with locally advanced gastric cancer (LAGC) who have received neoadjuvant immunochemotherapy (NAIC), it has been recognized that adjuvant chemotherapy after operation is indispensable for the majority of cases; nevertheless, whether additional postoperative adjuvant immunotherapy is needed is st...
Wei-Jun Zhang, Zhuo-Yu Jia, Qi Liu et al.· Journal of Gastrointestinal...· 0 citations
There was significant observed OS increase in patients 65-74 and 75-84 but not in patients <65 and ≥ 85, highlighting the necessity for further research into standard adjuvant therapies for patients with early stage PDAC by various age groups.
M. Farrar, Nupur Shridhar, Mason D. Stillman et al.· Journal of Geriatric Oncolog...· 0 citations
Background/Aim: Invasive urothelial carcinoma of the urinary bladder carries a high risk of micrometastatic spread, and perioperative chemotherapy is a key component of curative-intent treatment. Neoadjuvant chemotherapy (NAC) has the strongest supporting evidence, whereas the role of adjuvant chemotherapy (AC) remains...
Hao-Wei Chen, Jian-Ri Li, Shian-Shiang Wang et al.· Anticancer Research· 0 citations
Abstract Background Perioperative chemotherapy is the standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients...
Aravind Sreeram, Celine Yeh, N. Toumbacaris et al.· The Oncologist· 0 citations
BACKGROUND/AIMS
Managing early oral squamous cell carcinoma (OSCC) with a solitary ipsilateral lymph node metastasis (pN1) and no additional adverse features remains controversial, with conflicting international guidelines. Our study examined the effect of postoperative radiotherapy (PORT) compared with surgery only (S...
A. Alkhateeb, B. Hawas, R. Brinks et al.· Journal of cranio-maxillo-fa...· 0 citations
Although associated with increased postoperative morbidity, extended lymphadenectomy improves nodal assessment and staging accuracy in patients with GBC undergoing radical resection and may provide additional oncological benefits.
T. Chen, Y. Jin, Jun-Ke Wang et al.· Annals of Surgical Oncology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.